IndraLab
Statements
reach
"As expected, the MAPK inhibitor U0126 effectively decreased p-ERK1/2 protein expression (0.01 +/-0.01-fold versus 1 +/-0.2-fold vehicle treated, P < 0.001), and the PI3K inhibitor LY294002 decreased p-Akt (0.01 +/-0.01-fold versus 1 +/-0.09-fold vehicle treated), downstream Akt target p-mTOR (0.5 +/-0.2-fold versus 1 +/-0.2-fold vehicle treated), downstream mTOR target p-70S6 kinase (0.02 +/-0.02-fold versus 1 +/-0.1-fold vehicle treated)."